Catalyst Pharma director exits at $31.50 merger price
Catalyst Pharmaceuticals director David S. Tierney reported the disposition of 383,314 shares of common stock at $31.50 per share to the issuer on July 15, 2026, in connection with the acquisition by Angelini Pharma S.p.A.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Catalyst Pharmaceuticals director David S. Tierney reported the disposition of 383,314 shares of common stock at $31.50 per share to the issuer on July 15, 2026, in connection with the acquisition by Angelini Pharma S.p.A. All reported RSUs and fully vested stock options were cancelled at closing and converted into cash based on the $31.50 merger price, leaving no reported remaining holdings of these securities.
Insider Trade Summary
Disposition: 561,477 shares
Disposition
11 txns
Insider
Tierney David S
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Options to purchase common stock F3, F5 | 33,500 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F5 | 30,000 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F5 | 20,000 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F5 | 15,000 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F6 | 29,524 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F6 | 23,248 | $0.00 | $0.00 |
| Disposition | Options to purchase common stock F3, F6 | 18,115 | $0.00 | $0.00 |
| Disposition | Restricted Stock Units F2, F4, F6 | 1,414 | $0.00 | $0.00 |
| Disposition | Restricted Stock Units F2, F4, F6 | 1,894 | $0.00 | $0.00 |
| Disposition | Restricted Stock Units F2, F4, F6 | 5,468 | $0.00 | $0.00 |
| Disposition | Common Stock, par value $0.001 per share F1 | 383,314 | $31.50 | $12.07M |
Holdings After Transaction:
Options to purchase common stock — 0 contracts (Direct);
Restricted Stock Units — 0 contracts (Direct);
Common Stock, par value $0.001 per share — 0 shares (Direct)
Footnotes (6)
- F1. The reported securities were disposed of in connection with the consummation of the acquisition of the Issuer by Angelini Pharma S.p.A. (the "Merger")
- F2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F3. In connection with the consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share over the per-share price of such Option, multiplied by (y) the total number of shares subject to such Option.
- F4. In connection with the consummation of the Merger, each reported restricted stock unit ("RSU") was cancelled and converted into the right to receive a cash payment (without interest, and less applicable tax withholdings and other authorized deductions) equal to the product of (x) the excess of $31.50 per share, multiplied by (y) the number of shares subject to such RSU.
- F5. Each Option was fully vested.
- F6. Each Option or RSU, as applicable, vested in full in connection with the consummation of the Merger.
Key Figures
Common shares disposed: 383,314 shares
Merger cash price per share: $31.50 per share
RSUs cancelled (2032-11-20 grant): 5,468 units
+3 more
6 metrics
Common shares disposed
383,314 shares
Disposition of common stock to issuer on 2026-07-15 in connection with the Angelini Pharma merger
Merger cash price per share
$31.50 per share
Price paid for common stock and used to calculate cash for RSUs and options
RSUs cancelled (2032-11-20 grant)
5,468 units
Restricted Stock Units cancelled and cashed out at merger; underlying 5,468 common shares, expiring 2028-11-20
Stock options cancelled at $22.77 strike
18,115 options
Options to purchase common stock with $22.77 exercise price, expiring 2032-11-20, cancelled for cash
Stock options cancelled at $21.12 strike
23,248 options
Options to purchase common stock with $21.12 exercise price, expiring 2031-11-21, cancelled for cash
Reported holdings after transactions
0 shares or units
Total shares or units following each reported common stock, RSU and option disposition
Key Terms
Restricted Stock Units, Options to purchase common stock, Disposition to issuer, Angelini Pharma S.p.A., +1 more
5 terms
Restricted Stock Units financial
"The reported securities include Restricted Stock Units cancelled and cashed out at the Merger"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Options to purchase common stock financial
"Each reported Option to purchase common stock was cancelled and converted into a cash payment"
Disposition to issuer financial
"Transaction code D is described as a Disposition to issuer for the reported securities"
Angelini Pharma S.p.A. financial
"Securities were disposed of in the acquisition of the Issuer by Angelini Pharma S.p.A."
Merger financial
"The acquisition of the Issuer by Angelini Pharma S.p.A. is defined as the Merger"
A merger is when two companies combine into a single business, with ownership and control reorganized so they operate as one entity. For investors it matters because mergers can change the value and risk of holdings—shares may be exchanged, diluted, or rise if the combined company saves costs or gains market power, and the deal often depends on regulatory approval and successful integration like two households joining resources and routines.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Catalyst Pharmaceuticals (CPRX) disclose for David S. Tierney?
David S. Tierney disposed of 383,314 Catalyst Pharmaceuticals common shares at $31.50 per share in a disposition to the issuer. This occurred upon closing of the Angelini Pharma S.p.A. acquisition, alongside cash-out of his reported RSUs and stock options.
How was the $31.50 merger price applied to David S. Tierney’s CPRX equity?
The $31.50 per-share merger price was paid for his common stock and used to calculate cash for RSUs and options. RSUs were cashed out at $31.50 per unit, while options received cash equal to $31.50 minus the option’s exercise price, times shares.
What happened to David S. Tierney’s restricted stock units in Catalyst Pharmaceuticals (CPRX)?
All reported restricted stock units (RSUs) vested in full and were cancelled when the Angelini merger closed. Each RSU converted into a cash payment based on the $31.50 per-share merger price, less applicable tax withholdings and other authorized deductions.
What occurred to David S. Tierney’s stock options in CPRX after the Angelini merger?
All reported options to purchase Catalyst common stock were fully vested, cancelled and cashed out at closing. Each option generated a cash payment equal to ($31.50 minus its exercise price) multiplied by the number of underlying shares, subject to tax withholdings.
Does David S. Tierney report any remaining Catalyst Pharmaceuticals (CPRX) equity after these transactions?
Following the merger-related dispositions, the Form 4 shows 0 shares or units remaining for each reported common stock, RSU, and option position. This indicates no reported remaining holdings in those specific Catalyst equity awards after the Angelini Pharma acquisition closed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
